Full-Time

Analytical Sciences & Technology Associate Director

Updated on 3/14/2025

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$152.8k - $229.2kAnnually

+ Bonus + Equity Awards

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid-Eligible: work remotely up to two days per week.

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • Demonstrated expertise in biological assay development, validation, transfer, and troubleshooting compliant with GMP operations of Bio-CGT potency methods, including in-vitro cell-based functional/potency methods, in late-stage or commercial environments with a good understanding of GMP operation (required)
  • Exceptional writing skills for technical documents, regulatory submissions and responses, investigations, and change controls, with a proven ability to collaborate in a matrix environment (required)
  • Demonstrated proficiency with regulatory requirements, USP, and ICH guidelines (ICH Q2(R2))
  • Experience in managing contract testing sites (CROs, CMOs) for biologics method development, characterization, technology transfer, and Quality Testing
  • Extensive knowledge of Benefit-Risk strategies, problem-solving/root cause analysis for analytical-related issues, and decision-making with the ability to influence colleagues.
  • Strong time management and organizational skills with the ability to prioritize multiple projects in a fast-paced environment.
Responsibilities
  • Accountable for the strategy and execution of potency methods activities (development, gap analysis, validation, transfer, continuous improvement, reference standard strategy) to support late-stage programs and manage the analytical lifecycle of commercial programs.
  • Responsible for the strategic development of potency method transfer and validation. Design validation studies following ICH and FDA guidelines, review and approve plans, protocols, deviations, investigations, data, and summary reports.
  • Author and review regulatory documents during Biological License Applications (BLA), & Post Approval Submissions (PAS), and responses to Follow Up Measures (FUMs), Post Marketing Commitments (PMCs), and commercial readiness (including site inspection).
  • Collaborate with internal and external stakeholders to develop effective strategies for analytical activities by providing technical leadership for commercial GMP manufacturing and testing, focusing on method troubleshooting, quality events, change controls, and data trending to enhance commercial supply efficiency.
  • Represent AS&T on CMC teams to influence product development and build stakeholder relationships. Collaborate on technical, compliance, and regulatory strategies for the maintenance of Vertex products with suppliers.
  • Own/Review/Approve commercial documents to support new and existing commercial products (methods, SOPs, technical protocols/reports, change controls, etc.), and their continual improvement/update to ensure compliance and technical content.
  • Review potency regulatory guidance documents for the testing of biological products and advise on actions that could adversely affect the program or represent opportunities to be pursued.
  • Be accountable for the success of AS&T activities, project planning, prioritization, managing timelines, and ensuring the quality of deliverables to meet program commitments.
Desired Qualifications
  • Hands-on experience with flowcytometry assays for CGT products (desirable)
  • Experience in critical evaluation and interpretation of data, visualization tools, and statistical analysis tools (e.g., JMP) and/or sufficient knowledge of statistical concepts (preferred)
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Orna Therapeutics enhances Vertex's gene-editing capabilities.
  • Strong investor confidence shown by recent investments from JSF Financial and Channel Wealth.
  • Vertex's non-opioid pain therapies address the opioid crisis, offering market opportunities.

What critics are saying

  • Vertex is under investigation for potential securities law violations.
  • Mixed Phase II data for suzetrigine may delay its development timeline.
  • $1.07 billion investment in Orna partnership poses financial risk if outcomes fall short.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic biotech partnerships.
  • Vertex's innovative gene-editing therapies target unmet medical needs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

GlobeNewswire
Mar 18th, 2025
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into...

MarketBeat
Feb 14th, 2025
JSF Financial LLC Invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

MarketBeat
Jan 17th, 2025
Channel Wealth LLC Invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Channel Wealth LLC invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Zenopa
Jan 8th, 2025
Vertex and Orna Partner for Innovative Gene Therapy Solutions

In a significant advancement for the biopharma industry, Vertex Pharmaceuticals has announced a partnership with Orna Therapeutics to develop cutting-edge in vivo gene editing therapies targeting sickle cell disease and beta thalassaemia.

Pipeline Review
Jan 8th, 2025
Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

We look forward to partnering with Vertex to develop transformative therapies for SCD and TDT, while simultaneously advancing our lead panCAR(TM) pipeline programs in autoimmune and oncology.